Codis Expands Manufacturing Capabilities with New Investment
Codis, a Contract Development and Manufacturing Organization (CDMO) specializing in spray drying and particle engineering, has announced a substantial growth investment aimed at enhancing its commercial manufacturing capacity. This funding round was led by 1315 Capital, with additional support from existing shareholders such as BroadOak Capital Partners and Research Corporation Technologies (RCT).
Strategic Plans for Haverhill Facility
The investment is particularly focused on expanding the Haverhill facility in the UK. With over 400,000 square feet of current Good Manufacturing Practices (cGMP) approved space across multiple sites in the US and UK, Codis is positioned to significantly enhance its operational scale. The facility is capable of producing more than 5,000 metric tons per year of spray-dried product, making it one of the largest commercial spray-drying platforms globally.
Leadership Insights on the Investment
In a statement regarding the partnership, Nicolas Fortin, the CEO of Codis, expressed enthusiasm about welcoming 1315 Capital. "This investment will allow us to expand our capacity in Haverhill, enabling us to support more customers transitioning to commercial supply effectively," he noted. This sentiment was echoed by Matthew Reber, Partner at 1315 Capital, who highlighted the increasing need for specialized spray-drying expertise in the pharmaceutical sector, especially for producing amorphous solid dispersions and functional excipients.
Commitment to Quality and Global Reach
Shaun Kirkpatrick, President of Biotechnologies at RCT, stated that this investment reinforces Codis's established foundation of scale and quality. The unique capabilities at Codis not only support current client needs but also strategically position the company for future growth in the global health markets. Derek Hennecke, Chairman of the Board, remarked that strengthening the Haverhill site enhances the company’s global commercial network and streamlines supply times for clients.
Understanding the Impact of Codis's Growth
As Codis continues to develop its manufacturing capabilities, it remains a key player in the pharmaceutical, consumer health, nutraceutical, and over-the-counter (OTC) markets. The company operates through its advanced facilities to meet the demands of an evolving market that increasingly relies on sophisticated drug delivery technologies. With a history of regulatory compliance and industry experience, Codis is well-equipped to meet the needs of companies looking for extensive manufacturing expertise.
About Codis
Codis is a leading global CDMO specializing in spray drying, particle engineering, and finished dose manufacturing for various sectors, including pharmaceuticals and nutraceuticals. The breadth of experience and infrastructure allows Codis to blend innovative technology with regulatory strength, making it a trusted partner for many healthcare organizations.
About 1315 Capital
1315 Capital is a prominent healthcare-focused private equity firm managing over $1 billion in assets. The firm specializes in growth equity investments as well as buyouts of commercial healthcare companies. This experience provides Codis with strategic insights and resources necessary for scaling its operations.
About BroadOak Capital Partners
BroadOak Capital Partners offers direct investments in life science sectors, focusing on diagnostic and biopharma services. With a diverse portfolio, BroadOak supports growth across various stages of company development within this dynamic industry.
About Research Corporation Technologies
Research Corporation Technologies is centered on advancing technology and product development for life sciences. By managing significant investment portfolios, RCT provides substantial support to innovative biomedical companies.
Frequently Asked Questions
What is the goal of Codis's recent investment?
The goal is to expand its commercial manufacturing capacity, particularly at the Haverhill facility in the UK, to better serve its clients.
Who are the major investors involved in this funding round?
The major investors include 1315 Capital, BroadOak Capital Partners, and Research Corporation Technologies.
What manufacturing capabilities does Codis possess?
Codis has over 400,000 square feet of cGMP space and can produce more than 5,000 metric tons of spray-dried products annually.
How does this investment enhance Codis's market presence?
This investment allows Codis to improve its manufacturing capabilities, thereby supporting more clients in the pharmaceutical and health sectors effectively.
What does Codis specialize in?
Codis specializes in spray drying, amorphous solid dispersions, particle engineering, and finished-dose manufacturing for various sector needs.
